Produção Nacional
Revisado por pares
POS1016 THE IMPACT OF ACTIVE LUPUS NEPHRITIS ON WORK PRODUCTIVITY IN PATIENTS FROM A LATIN AMERICAN LUPUS COHORT
2024; BMJ; Linguagem: Inglês
10.1136/annrheumdis-2024-eular.2272
ISSN1468-2060
AutoresGuillermo J. Pons‐Estel, Rubén Nieto, R. Quintana, D. C. Fernández Ávila, Rosa Serrano, Guillermina Harvey, L. Hernández, K. Roberts, Luís J. Catoggio, G. C. Subils, C. Gobbi, F. Bordon, P. D. Ibañez Peña, L. A. Berbotto, M. C. Bertolaccini, D. O. Rinesi, María de los Ángeles Gargiulo, Cecilia Pisoni, J. Serventi, E. Buschiazzo, Vitalina de Souza Barbosa, Odirlei André Monticielo, C. Albanez de A. Da C. Andrade, F. Machado Ribeiro, Eloísa Bonfá, Eduardo Ferreira Borba, Emília Inoue Sato, A. Bondi, Sebastián Donoso, Gustavo Aroca, Humberto R. Medina, Á. García, Sebastián Molina-Ríos, M. Rubio Rivera, Roberto Martínez, M. Moreno Álvarez, Olga Vera‐Lastra, Mario Pérez Cristóbal, Cecilia Alvarez, Luís M. Amezcua‐Guerra, Ignacio García-Valladares, Carlos Abud‐Mendoza, D. A. Galarza-Delgado, Marcos Vázquez, Astrid Paats, J. N. Cieza Calderón, Alicia Alva-Mantari, R. Muñoz Louis, Carlos Pizzarossa, A. Carlomango, Rocío V. Gamboa‐Cárdenas, Graciela S. Alarcón, U. Sbarigia, F. Zazzetti, Ashley Orillion, Bernardo A. Pons‐Estel,
Tópico(s)Systemic Lupus Erythematosus Research
ResumoBackground: Lupus nephritis (LN) is one of the most common, serious manifestations of systemic lupus erythematosus (SLE) and is associated with significant morbidity and mortality. Objectives: To evaluate work productivity (WP) and activity impairment (AI) in patients with active LN at cohort entry and 12 months after treatment initiation according to their renal response. Methods: GLADEL 2.0 is an observational prevalent and incident cohort. Forty-four centers from Latin-American countries enrolled patients ≥18 years of age who fulfilled the 1982/1997 American College of Rheumatology (ACR) and/or the 2012 Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for SLE. Patients from different subsets of LN were enrolled. For this analysis, patients in Group II (prevalent inactive LN), III (prevalent active LN) and IV (incident LN) and 12-month follow-up data were included. Demographic, clinical manifestations, disease activity (SLEDAI- 2k) and damage SLICC/ACR Damage Index (SDI) were examined. At baseline, WPAI scores stratified by the presence of active or inactive LN were compared. At 12 months, absenteeism, presenteeism, global work impairment in employed patients and AI in patients with active LN were compared according to their renal response. Renal responses were defined according to EULAR/KDIGO: Complete clinical response: UPCR < 0.5 g/g; Partial clinical response: ≥50% reduction in UPCR, No Response: <50% reduction in proteinuria. Descriptive analyses were performed. Results: Of the 1081 patients included in the cohort, 651 with history of LN were evaluated (423 with active LN and 228 with inactive LN). Of the active LN patients, 369 (87.4%) were women, were younger at cohort entry, of a lower socioeconomic status, had a higher unemployment rate and a higher SLEDAI than patients with inactive LN. Of the LN patients, 257 (39.5%) were employed (salaried work) at cohort entry and were included in this analysis. Patients with active LN showed higher rates of impairment in the WPAI score with greater impact and lower WP in all domains than in patients with inactive LN (Table 1). At 12 months, there was no evidence of a positive impact on WP as measured by the WPAI in patients who achieved renal response (Table 2). Conclusion: Patients with active LN presented a greater impairment on WP compared to patients with inactive LN. There was no evidence of a positive impact on WP in patients who achieved a complete or partial renal response after 12 months of treatment. Future analyses with a larger number of patients being followed up would be necessary to provide more definitive data. REFERENCES: NIL. Acknowledgements: Medical writing support was provided by Panita Maturavongsadit, PhD, of Lumanity Communications Inc., and was funded by Janssen Global Services, LLC. Disclosure of Interests: Guillermo Pons-Estel AstraZeneca, Boehringer Ingelheim, GSK, Janssen, Novartis, Pfizer, RemeGen, Sanofi and Werfen Diagnostics, AstraZeneca, Boehringer Ingelheim, GSK, Janssen, Novartis, Pfizer, RemeGen, Sanofi and Werfen Diagnostics, AstraZeneca, Boehringer Ingelheim, GSK, Janssen, Novartis, Pfizer, RemeGen, Sanofi and Werfen Diagnostics, Romina Nieto: None declared, Rosana Quintana: None declared, Diana Carolina Fernández Ávila: None declared, Rosa Serrano: None declared, Guillermina Harvey: None declared, Lucia Hernández: None declared, Karen Roberts: None declared, Luis Catoggio: None declared, Gislea Subils: None declared, Carla Gobbi: None declared, Florencia Bordon: None declared, Pablo David Ibañez Peña: None declared, Leonel Ariel Berbotto: None declared, María Constanza Bertolaccini: None declared, Diego O. Rinesi: None declared, Maria de los Ángeles Gargiulo: None declared, Cecilia Pisoni: None declared, Joaquín Martínez Serventi: None declared, Emilio Buschiazzo: None declared, Vitalina Barbosa: None declared, Odirlei André Monticielo: None declared, Carolina Albanez de A. Da C. Andrade: None declared, Francinne Machado Ribeiro: None declared, Eloisa Bonfa: None declared, Eduardo F. Borba: None declared, Emília I. Sato: None declared, Alexis Peralta Bondi: None declared, Silvana Donoso: None declared, Gustavo Aroca Martínez: None declared, Hellen Medina: None declared, Alex Echeverri: None declared, Sebastian Molina-Rios: None declared, Manuela Rubio Rivera: None declared, Rafael Lopez Martinez: None declared, Mario Moreno Alvarez: None declared, Olga L. Vera Lastra: None declared, Mario Pérez Cristóbal: None declared, Carlos Núñez Álvarez: None declared, Luis M. Amezcua-Guerra: None declared, Ignacio García-Valladares: None declared, Carlos Abud Mendoza: None declared, Dionicio A. Galarza-Delgado: None declared, Marcos Vázquez: None declared, Astrid Paats: None declared, Jorge N. Cieza Calderón: None declared, Ana Mabel Quiros Alva: None declared, Roberto Muñoz Louis: None declared, Carina Pizzarossa: None declared, Adriana Carlomango: None declared, Rocío V. Gamboa-Cardenas: None declared, Graciela S. Alarcón: None declared, Urbano Sbarigia Johnson & Johnson, Johnson & Johnson, Federico Zazzetti Johnson & Johnson, Johnson & Johnson, Ashley Orillion Johnson & Johnson, Johnson & Johnson, Bernardo Pons-Estel AstraZeneca, GSK, and Janssen.
Referência(s)